Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quetiapine fumarate + antidepressant
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination therapy involving **quetiapine fumarate**, an atypical antipsychotic, and an **antidepressant** (the specific agent is not defined; most studies involve SSRIs or SNRIs), used primarily as an **adjunctive treatment for major depressive disorder (MDD) and treatment-resistant depression**. Quetiapine acts as an antagonist at serotonin 5-HT2A, dopamine D2, and several other neurotransmitter receptors, while antidepressants commonly included in such combinations act primarily on serotonin and/or norepinephrine reuptake inhibition. Combination regimens are intended to improve depressive symptoms, quality of sleep, and anxiety, particularly in cases where monotherapy is insufficient. Quetiapine has sedative, anxiolytic, and mood-stabilizing properties, and is also indicated adjunctively in bipolar depression and for symptoms of schizophrenia[1][2][4][5].
- Brand names
- Seroquel
- Other names
- SSRI/SNRI and Quetiapine combination therapyAdjunctive Quetiapine with Antidepressants
02
Targets
DRD4 (Dopamine D4 Receptor)HTR2A (Serotonin receptor 5-HT2A)SERT (Sodium-dependent serotonin transporter)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2C (5-hydroxytryptamine 2C receptor)HRH1 (Histamine H1 Receptor)M1 (Muscarinic acetylcholine receptor M1)ADRA1A (α1A)ADRA2A (α2A)DRD1 (Dopamine D1 Receptor)HTR7 (5-hydroxytryptamine receptor 7)DRD2 (Dopamine D2 Receptor)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on quetiapine fumarate + antidepressant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quetiapine fumarate + antidepressant.